Apixaban in patients with atrial fibrillation.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  New England Journal of Medicine

• Publication date

  2011-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1007432PMID 21309657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-Term Follow-Up of Recipients of Combined Human Leukocyte Antigen-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With End-Stage Renal Disease

  2011cited by this paper
• Management of atrial fibrillation.

  2010cited by this paper
• Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation

  2010cited by this paper
• Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke

  2010cited by this paper
• Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

  2010cited by this paper
• Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

  2010cited by this paper
• Update on Antithrombotic Therapy: New Anticoagulants

  2010cited by this paper
• Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.

  2010cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

  2009cited by this paper
• Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States

  2009cited by this paper
• Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

  2009cited by this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation.

  2007cited by this paper
• Management of atrial fibrillation.

  2007cited by this paper
• Low Priority of Cardiovascular and Chronic Diseases on the Global Health Agenda: A Cause for Concern

  2007cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses

  2006cited by this paper
• Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation

  2006cited by this paper
• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

  2006cited by this paper
• Toward Transplantation Tolerance: A Large Step on a Long Road

  2006cited by this paper
• Low-dose aspirin for the prevention of atherothrombosis.

  2005cited by this paper
• Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas

  2005cited by this paper
• Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.

  2005cited by this paper
• Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience.

  2004cited by this paper
• Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

  2003cited by this paper
• Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen

  1989cited by this paper

• Non-inferiority clinical trials: What they are and when they should be done.

  2026cites this paper
• Antithrombotic therapy in patients with atrial fibrillation: unresolved issues and future directions.

  2026cites this paper
• The impact of ischemic stroke and intracerebral hemorrhage with non-Vitamin K antagonist oral anticoagulants in patients with paroxysmal and persistent atrial fibrillation: A population based cohort study

  2026cites this paper
• A Year in Review: Atrial Fibrillation 2025

  2026cites this paper
• Understanding the use, benefit and harms of directly acting oral anticoagulants over the COVID-19 period: Protocol for National Health Service England Secure Data Environment study

  2026cites this paper
• Effectiveness and Safety of Direct Oral Anticoagulants versus Aspirin in Patients with Non-Valvular Atrial Fibrillation and Intermediate Stroke Risk

  2026cites this paper
• Left atrial appendage occlusion versus NOACs in patients with atrial fibrillation: Rationale and design of the CATALYST Trial.

  2026cites this paper
• Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy

  2025cites this paper
• Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke.

  2025cites this paper
• Anticoagulants: From chance discovery to structure-based design.

  2025cites this paper
• Comparative efficacy and safety of anticoagulant therapies in coronary artery disease: a network meta-analysis of randomized controlled trials

  2025cites this paper
• Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.

  2025cites this paper
• Bleeding Risks With Non–Vitamin K Oral Anticoagulants Versus Single Antiplatelet Therapy

  2025cites this paper
• Management of carotid artery web: a nationwide survey of vascular neurologists versus neurointerventionalists

  2025cites this paper
• Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis

  2025cites this paper
• Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.

  2025cites this paper
• Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation-Reply.

  2025cites this paper
• Clinical Perspectives on Stroke Prevention in Patients with Non-valvular Atrial Fibrillation in the Philippines

  2025cites this paper
• Antithrombotic Monotherapy or Combination Therapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Meta‐Analysis of Randomized Trials

  2025cites this paper
• Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.

  2025cites this paper
• Comparison of Apixaban with Warfarin for the Prevention of Subclinical Cerebral Infarction after Direct Current Cardioversion in Patients with Atrial Fibrillation

  2025cites this paper
• Diagnosis and management of cerebral amyloid angiopathy: a scientific statement from the International CAA Association and the World Stroke Organization

  2025cites this paper
• Clinical Effectiveness of Transcatheter Left Atrial Appendage Occlusion With Watchman FLX Compared With First-Generation Watchman.

  2025cites this paper
• Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation

  2025cites this paper
• Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions

  2025cites this paper
• Novel Genotoxic Impurities in the First-Line Oral Anticoagulant Drug, Apixaban: Computational Toxicological Evaluation and Development of a Highly Sensitive LC-MS/MS Quantification Method.

  2025cites this paper
• Ablation of atrial fibrillation and risk of stroke: a Meta-analysis.

  2025cites this paper
• Factor XI inhibitors and atrial fibrillation: imminent breakthrough or false start?

  2025cites this paper
• Cerebrovascular Management Considerations in Patients on AATs

  2025cites this paper
• MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial

  2025cites this paper
• Increased direct oral anticoagulant use and event rates in non-valvular atrial fibrillation: a nationwide retrospective registry study in Sweden

  2025cites this paper
• On Neurocardiology Updates: an Interdisciplinary Field at the Intersection of Neurology and Cardiology

  2025cites this paper
• Artificial Intelligence-Enhanced Electrocardiography for Prediction of Occult Atrial Fibrillation in Patients With Stroke Who Undergo Prolonged Cardiac Monitoring.

  2025cites this paper
• Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.

  2025cites this paper
• Edoxaban Safety and Effectiveness in Real-Life Patients with Heart Failure and Atrial Fibrillation: EMAYIC Study

  2025cites this paper
• Association between first anticoagulant prescription and embolic and hemorrhagic events among older adults with atrial fibrillation

  2025cites this paper
• Switching From Aspirin Monotherapy After Noncardioembolic Stroke: A Systematic Review and Network Meta-Analysis.

  2025cites this paper
• Clinical Outcomes of Direct Oral Anticoagulant Off-label Dosing in Nonvalvular Atrial Fibrillation

  2025cites this paper
• Menstrual bleeding-specific quality of life in women on antiplatelet therapy

  2025cites this paper
• Anticoagulation for Stroke Prevention in Patients with Atrial Fibrillation: A Review of the Literature and Current Guidelines

  2025cites this paper
• Antithrombotic Management in Catheter Ablation for ventricular arrhythmias -Mini review.

  2025cites this paper
• Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update

  2025cites this paper
• Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.

  2025cites this paper
• Chinese expert consensus on prevention, diagnosis, and management of venous thromboembolism in adult burn patients (2024)

  2025cites this paper
• Exploring Apixaban Interaction with Heptakis(2,6-di-O-methyl)-β-Cyclodextrin: Insights from Phase Solubility Diagrams, 1H NMR and Molecular Dynamics Simulations

  2025cites this paper
• Long-term antithrombotic therapy practices in adult patients with short bowel syndrome following acute mesenteric ischemia: an international case-based survey.

  2025cites this paper
• Real-world apixaban concentration in Korean patients with atrial fibrillation

  2025cites this paper
• Clinical Management of Cerebral Amyloid Angiopathy

  2025cites this paper
• Risk of Intracranial Hemorrhage With Apixaban Versus Aspirin Therapy: A Meta-Analysis of Randomized Controlled Trials.

  2025cites this paper
• New drugs and their performance 10 years after approval: a systematic analysis

  2025cites this paper
• Anticoagulation in patients with low-burden atrial fibrillation: new evidence focussing on device-detected AF

  2025cites this paper
• Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran

  2024cites this paper
• Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation: A Pooled Analysis of the NOAH-AFNET 6 and ARTESiA Trials.

  2024cites this paper
• Refining Stroke Risk Assessment in Patients with Device-Detected Atrial Fibrillation

  2024cites this paper
• Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects

  2024cites this paper
• An International Consensus Practical Guide on Left Atrial Appendage Closure for the Non-implanting Physician: Executive Summary

  2024cites this paper
• Cost-Minimization Model in Cryptogenic Stroke: ePatch vs Implantable Loop Recorder in Patients from the UK, Netherlands, and Sweden

  2024cites this paper
• Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions.

  2024cites this paper
• Anticoagulants : utilisation pratique

  2024cites this paper
• Leveraging Mendelian randomization to inform drug discovery and development for ischemic stroke.

  2024cites this paper
• Impact of Renal Function Estimation Formulae on Use and Correct Dosing of NOACs in Patients with Non-valvular Atrial Fibrillation in Real Life in Germany

  2024cites this paper
• Risk of Intracranial Hemorrhage Associated With Direct Oral Anticoagulation vs Antiplatelet Therapy

  2024cites this paper
• Genetic Determinants of Left Atrial Function Are Associated With Stroke

  2024cites this paper
• Embolic Stroke of Undetermined Source

  2024cites this paper
• Apixaban plasma concentrations in patients with obesity

  2024cites this paper
• Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS

  2024cites this paper
• Abstracts from the World Congress of Cardiology/Oriental Congress of Cardiology 2024

  2024cites this paper
• The impact of chronic kidney disease on prognosis in acute stroke: unraveling the pathophysiology and clinical complexity for optimal management

  2024cites this paper
• Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.

  2024cites this paper
• When to prescribe oral anticoagulation for patients with device-detected subclinical atrial fibrillation? Insights from the NOAH-AFNET 6 and ARTESiA trials.

  2024cites this paper
• Oral anticoagulants and cognitive impairment in patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis.

  2024cites this paper
• Subclinical atrial fibrillation patients, who are the best candidates for oral anticoagulant therapy?

  2024cites this paper
• Precision Monitoring of Antithrombotic Therapy in Cardiovascular Disease

  2024influential citation
• Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and Benefits.

  2024cites this paper
• Efficacy and safety of Apixaban in the treatment of cerebral venous sinus thrombosis: a multi-center study

  2024cites this paper
• Predictors for Adherence to Recommended Anticoagulation after Stroke Unit Discharge in Patients with Atrial Fibrillation

  2024cites this paper
• Drug-related problems associated with direct oral anticoagulants: an observational cross-sectional study of medical record review by pharmacists in a large teaching hospital

  2024cites this paper
• Novel stroke prevention strategies following catheter ablation for atrial fibrillation.

  2024cites this paper
• Antiplatelet period drama: a rush of blood or classic crimson tide?

  2024cites this paper
• Atrial Fibrillation Detection and Ischemic Stroke Recurrence in Cryptogenic Stroke: A Retrospective, Multicenter, Observational Study

  2024cites this paper
• Oral Anticoagulation for hemodialysis patients with atrial fibrillation: the therapeutic conundrum remains.

  2024cites this paper
• Dual Antiplatelet Therapy for the Acute Management and Long-term Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack, An Updated Review

  2024cites this paper
• Fondamentaux de l’évaluation des thérapeutiques, médicamenteuses et non médicamenteuses – un cadre pour l’évaluation des processus d’autoguérison

  2024cites this paper
• Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.

  2024cites this paper
• Left atrial appendage occlusion for patients with valvular diseases without atrial fibrillation (the OPINION Study): study protocol for a multicentre, randomised controlled trial

  2024cites this paper
• Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations.

  2024cites this paper
• Epicardial left atrial appendage clipping versus direct oral anticoagulant to reduce stroke risk in non-paroxysmal atrial fibrillation (LAA-CLIP): rationale, design and study protocol for a multicentre randomised controlled trial

  2024cites this paper
• Cardiovascular Management in Asymptomatic (Silent) Cerebral Microbleeds and Suspected Cerebral Amyloid Angiopathy

  2024cites this paper
• Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure

  2024cites this paper
• Toward More Personalized Management of Device-Detected Atrial Fibrillation.

  2024cites this paper
• Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

  2024cites this paper
• Acute severe renal failure in a patient receiving apixaban: a case report

  2024cites this paper
• Management of atrial arrhythmias identified by cardiac devices

  2024cites this paper
• Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease With Recent or Remote Events: Systematic Review and Meta-analysis

  2024cites this paper
• Balancing the benefits and risks of anticoagulation in patients with subclinical atrial fibrillation.

  2024cites this paper
• Oral Anticoagulation in Device Patients With Atrial High-Rate Episodes: Shared Decision-Making After ARTESIA and NOAH-AFNET-6.

  2024cites this paper
• Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid

  2024cites this paper
• Anticoagulation in Atrial Fibrillation Patients With Renal Impairment

  2024cites this paper
• When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.

  2024cites this paper